{"id":5530,"date":"2026-02-26T17:47:54","date_gmt":"2026-02-26T17:47:54","guid":{"rendered":"https:\/\/regenerated.health\/edta-chelation\/"},"modified":"2026-06-25T14:28:19","modified_gmt":"2026-06-25T14:28:19","slug":"edta-chelation","status":"publish","type":"post","link":"https:\/\/regenerated.com\/blog\/edta-chelation\/","title":{"rendered":"EDTA Chelation Therapy: How It Works, the TACT Trial, and What the Evidence Shows"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\">EDTA Chelation: What It Is and How It Works<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">Ethylenediaminetetraacetic acid (EDTA) is a synthetic amino acid compound that has been used in medicine since the 1950s. Its defining property is chelation: the ability to bind metal ions and carry them out of the body through the kidneys. The word &#8220;chelation&#8221; comes from the Greek word &#8220;chele,&#8221; meaning claw, because the molecule literally grabs onto metal atoms with a claw-like molecular grip.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">EDTA chelation therapy has been FDA-approved for lead poisoning and hypercalcemia for decades. Its more controversial application is for cardiovascular disease, specifically atherosclerosis, where the theory is that removing calcium and toxic metals from arterial plaques may improve blood flow and reduce cardiovascular events. That theory was largely dismissed by mainstream medicine until a landmark NIH-funded trial produced results that surprised nearly everyone.<\/p>\n\n\n\n<div class=\"wp-block-group has-background\" style=\"background-color:#f0f7f4;border-radius:12px;padding:1.5em\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\">\n\n<h3 class=\"wp-block-heading\">At a Glance<\/h3>\n\n\n<ul class=\"wp-block-list\">\n<li>EDTA is a synthetic amino acid that binds heavy metals (lead, mercury, cadmium, calcium) and removes them through the kidneys.<\/li>\n<li>FDA-approved indications: lead poisoning and hypercalcemia. Off-label use for cardiovascular disease is the primary area of debate.<\/li>\n<li>The TACT trial (1,708 patients, NIH-funded) showed an 18% reduction in cardiovascular events in post-heart-attack patients receiving EDTA chelation, with a 41% reduction in diabetic patients.<\/li>\n<li>TACT2, the follow-up trial in diabetic patients, is providing additional data on these findings.<\/li>\n<li>IV EDTA is the standard clinical protocol. Oral EDTA has poor absorption (5 to 18%) and is not considered equivalent.<\/li>\n<li>Risks include hypocalcemia, kidney strain, and mineral depletion. Proper monitoring with lab work before and during treatment is essential.<\/li>\n<li>A typical treatment course costs $3,000 to $5,000 for 20 to 40 infusions.<\/li>\n<\/ul>\n\n<\/div><\/div>\n\n\n\n<h2 class=\"wp-block-heading\">The Mechanism: How EDTA Removes Metals<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">EDTA works through a straightforward chemical process. When infused intravenously, the EDTA molecule circulates through the bloodstream, where it encounters and binds to metal ions based on a specific affinity hierarchy. EDTA binds most strongly to lead, followed by iron, mercury, copper, calcium, zinc, cadmium, and other divalent and trivalent metals.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Once EDTA binds a metal ion, it forms a stable, water-soluble complex called a chelate. This chelate is too large to be reabsorbed by the kidneys and is excreted in the urine. The result is a measurable reduction in the circulating levels of the targeted metals within hours of infusion.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This is not selective. EDTA will bind essential minerals (calcium, zinc, magnesium, iron) along with toxic metals (lead, cadmium, mercury). This is why mineral supplementation and monitoring are required during a chelation course. The therapeutic strategy relies on the fact that your body can replace essential minerals through diet and supplementation, while the toxic metals it removes do not belong there in the first place.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">IV vs. Oral EDTA<\/h3>\n\n\n\n<figure class=\"wp-block-table is-style-stripes\"><table><thead><tr><th>Factor<\/th><th>IV EDTA<\/th><th>Oral EDTA<\/th><\/tr><\/thead><tbody><tr><td>Bioavailability<\/td><td>100% (direct bloodstream delivery)<\/td><td>5 to 18% absorption<\/td><\/tr><tr><td>Clinical evidence<\/td><td>TACT trial, decades of clinical use<\/td><td>Limited clinical data<\/td><\/tr><tr><td>Dose per session<\/td><td>1.5 to 3 grams (standard)<\/td><td>500 to 2,000 mg daily<\/td><\/tr><tr><td>Duration<\/td><td>1.5 to 3 hours per infusion<\/td><td>Daily oral dosing<\/td><\/tr><tr><td>Cost per session<\/td><td>$100 to $150<\/td><td>$30 to $60\/month<\/td><\/tr><tr><td>Monitoring required<\/td><td>Yes (kidney function, minerals)<\/td><td>Yes, though often skipped<\/td><\/tr><tr><td>FDA context<\/td><td>Approved for lead, studied in TACT<\/td><td>Not studied in major trials<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<div class=\"wp-block-group has-background\" style=\"background-color:#fff8e1;border-radius:12px;padding:1.5em\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\">\n\n<p class=\"wp-block-paragraph\"><strong>Clinical note:<\/strong> Oral EDTA supplements are widely available online, but their low bioavailability means they deliver a fraction of the dose used in clinical trials. The TACT trial used IV EDTA exclusively. Oral EDTA may have some value for ongoing low-level metal exposure, but it should not be considered a substitute for IV chelation when treating documented heavy metal toxicity or following the TACT protocol.<\/p>\n\n<\/div><\/div>\n\n\n\n<h2 class=\"wp-block-heading\">The TACT Trial: The Study That Changed the Conversation<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The Trial to Assess Chelation Therapy (TACT) is the single most important piece of evidence in the chelation debate. Funded by the National Institutes of Health (NIH) and the National Center for Complementary and Integrative Health (NCCIH), TACT was a rigorous, double-blind, placebo-controlled, randomized clinical trial. It was designed to settle the question of whether EDTA chelation has any legitimate role in cardiovascular medicine.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Study Design<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Patients:<\/strong> 1,708 adults aged 50 and older who had experienced a prior heart attack (myocardial infarction) at least 6 weeks before enrollment.<\/li>\n<li><strong>Treatment:<\/strong> 40 IV infusions of disodium EDTA (3 grams per infusion, mixed with ascorbic acid, B vitamins, magnesium, and other supplements) or matching placebo, given weekly for 30 weeks, then every 2 to 8 weeks for an additional 10 infusions.<\/li>\n<li><strong>Primary endpoint:<\/strong> A composite of death from any cause, heart attack, stroke, coronary revascularization, or hospitalization for angina.<\/li>\n<li><strong>Follow-up:<\/strong> Median of 55 months (approximately 4.6 years).<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Results<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The overall results showed a statistically significant 18% reduction in the primary composite endpoint in the EDTA chelation group compared to placebo (hazard ratio 0.82, 95% confidence interval 0.69 to 0.99, p=0.035). This means that patients who received EDTA chelation were 18% less likely to experience a major cardiovascular event during follow-up.<sup>1<\/sup><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The results in the pre-specified diabetic subgroup were far more dramatic. Among the 633 diabetic participants, EDTA chelation reduced the primary endpoint by 41% (hazard ratio 0.59, 95% confidence interval 0.44 to 0.79, p<0.001). The reduction in total mortality among diabetic patients was 43%.<sup>2<\/sup><\/p>\n\n\n\n<div class=\"wp-block-group has-background\" style=\"background-color:#fff8e1;border-radius:12px;padding:1.5em\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\">\n\n<p class=\"wp-block-paragraph\"><strong>Why diabetic patients?<\/strong> The leading hypothesis is that diabetic patients accumulate more toxic metals (particularly cadmium and lead) due to metabolic factors and longer exposure periods. These metals promote oxidative stress, endothelial dysfunction, and inflammation, all of which are already amplified in diabetes. Removing these metals may have outsized benefit in this population. Blood cadmium levels in TACT participants correlated with cardiovascular event risk, supporting the metal-toxicity mechanism.<sup>3<\/sup><\/p>\n\n<\/div><\/div>\n\n\n\n<h3 class=\"wp-block-heading\">TACT2: The Follow-Up<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Based on the striking results in diabetic patients, the NIH funded TACT2, a follow-up trial specifically enrolling diabetic patients with prior heart attacks. TACT2 enrolled approximately 1,000 patients across multiple centers and follows the same basic protocol as the original TACT trial. Results from TACT2 have been presented at major cardiology conferences and continue to inform the clinical picture. The trial is designed to confirm or refute the dramatic benefits seen in the TACT diabetic subgroup.<sup>4<\/sup><\/p>\n\n\n\n<h2 class=\"wp-block-heading\">FDA-Approved Uses<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">EDTA is FDA-approved for two specific conditions:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Lead poisoning:<\/strong> Calcium disodium EDTA (CaNa2EDTA) is the standard treatment for symptomatic lead poisoning, particularly in children. It is highly effective at reducing blood lead levels and preventing further organ damage.<\/li>\n<li><strong>Hypercalcemia:<\/strong> Disodium EDTA can be used for emergency treatment of dangerously elevated calcium levels, though this application is less common today due to the availability of other treatments.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">All other uses of EDTA chelation, including cardiovascular applications, are considered off-label. Off-label does not mean ineffective or illegitimate. It means the manufacturer has not pursued (or completed) the FDA approval process for that specific indication. Many widely accepted medical treatments are used off-label.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">The Provoked vs. Unprovoked Urine Testing Debate<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">One of the most contentious issues in chelation medicine is how heavy metal levels are measured. This matters because the decision to pursue chelation therapy often hinges on test results.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Unprovoked testing<\/strong> measures metal levels in blood or urine without administering a chelating agent first. This reflects your body&#8217;s current circulating metal burden.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Provoked (challenge) testing<\/strong> involves administering a dose of a chelating agent (EDTA, DMSA, or DMPS), then collecting urine for 6 to 24 hours. The chelator pulls metals out of tissues, so provoked urine levels are always higher than unprovoked levels.<\/p>\n\n\n\n<div class=\"wp-block-group has-background\" style=\"background-color:#fff3e0;border-radius:12px;padding:1.5em\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\">\n\n<p class=\"wp-block-paragraph\"><strong>The controversy:<\/strong> Some practitioners compare provoked urine results to unprovoked reference ranges, which makes metal levels appear artificially elevated. This is a methodological problem because the reference ranges were established without a chelation challenge. Provoked results should only be compared to provoked reference ranges. When this comparison error occurs, patients may be told they have &#8220;high&#8221; metal levels that would actually be normal for a provoked test. If a practitioner only offers provoked testing and compares results to unprovoked ranges, that is a red flag.<\/p>\n\n<\/div><\/div>\n\n\n\n<p class=\"wp-block-paragraph\">The most reliable approach is baseline unprovoked blood and urine testing, supplemented by provoked testing only when there is clinical suspicion of a significant tissue metal burden that baseline testing might miss. For more on testing options, see our guide to <a href=\"\/blog\/heavy-metal-testing\/\">heavy metal testing methods<\/a>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Standard EDTA Chelation Protocol<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The protocol used in the TACT trial has become the de facto standard for cardiovascular chelation therapy. It involves:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pre-treatment workup:<\/strong> Complete metabolic panel (kidney and liver function), complete blood count, urinalysis, baseline mineral levels (calcium, magnesium, zinc, iron), and a baseline heavy metal panel.<\/li>\n<li><strong>Infusion solution:<\/strong> 3 grams disodium EDTA mixed with 7 grams ascorbic acid, B vitamins (B1, B5, B6, B12), magnesium chloride, procaine (local anesthetic to reduce vein irritation), and sterile water. Total volume is approximately 500 mL.<\/li>\n<li><strong>Infusion rate:<\/strong> Administered over 1.5 to 3 hours. Faster infusion increases the risk of hypocalcemia and kidney strain.<\/li>\n<li><strong>Frequency:<\/strong> Weekly for the first 30 sessions, then biweekly to monthly for maintenance.<\/li>\n<li><strong>Total course:<\/strong> 20 to 40 infusions for an initial course. Some patients continue with maintenance infusions monthly or quarterly.<\/li>\n<li><strong>Monitoring:<\/strong> Kidney function (creatinine, BUN) checked every 5 to 10 infusions. Mineral levels checked periodically. Symptoms monitored at each visit.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">Side Effects and Risks<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Common Side Effects<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Burning or discomfort at the IV site:<\/strong> The most frequent complaint. Adding procaine to the infusion solution and using a larger vein reduces this.<\/li>\n<li><strong>Fatigue:<\/strong> Many patients feel tired for 12 to 24 hours after infusion. This typically improves as the body adjusts over the first few sessions.<\/li>\n<li><strong>Headache:<\/strong> Mild headache is common, especially in the first few sessions. Adequate hydration before and after infusion helps.<\/li>\n<li><strong>Nausea:<\/strong> Occasional, usually mild. Eating a light meal before infusion reduces this.<\/li>\n<li><strong>Temporary drop in blood pressure:<\/strong> EDTA can cause mild vasodilation. Patients should sit for 15 to 30 minutes after infusion before standing.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">Serious Risks<\/h3>\n\n\n\n<div class=\"wp-block-group has-background\" style=\"background-color:#fff3e0;border-radius:12px;padding:1.5em\"><div class=\"wp-block-group__inner-container is-layout-flow wp-block-group-is-layout-flow\">\n\n<ul class=\"wp-block-list\">\n<li><strong>Hypocalcemia:<\/strong> The most significant acute risk. EDTA binds calcium aggressively. If infusion is too fast or the dose is too high relative to the patient&#8217;s calcium stores, blood calcium can drop to dangerous levels. Symptoms include tingling in the fingers and around the mouth, muscle cramps, and in severe cases, cardiac arrhythmia. This is why infusion rate matters and why calcium levels should be monitored.<\/li>\n<li><strong>Kidney damage:<\/strong> EDTA is cleared through the kidneys, and high doses or rapid infusion can strain kidney function. Patients with pre-existing kidney disease are at higher risk. Creatinine levels must be checked regularly throughout treatment.<\/li>\n<li><strong>Mineral depletion:<\/strong> Extended chelation courses can deplete essential minerals (zinc, manganese, chromium) if supplementation is not maintained. This is preventable with proper monitoring and supplementation.<\/li>\n<li><strong>Bone marrow suppression:<\/strong> Rare at standard doses, but possible with prolonged high-dose treatment. Monitored through periodic complete blood counts.<\/li>\n<\/ul>\n\n<\/div><\/div>\n\n\n\n<p class=\"wp-block-paragraph\">In the TACT trial, the safety profile was reassuring. Serious adverse events were similar between the chelation and placebo groups. When EDTA chelation is administered at proper doses, at appropriate infusion rates, with adequate monitoring, it has a well-established safety record spanning decades of clinical use.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Cost and Insurance<\/h2>\n\n\n\n<figure class=\"wp-block-table is-style-stripes\"><table><thead><tr><th>Cost Component<\/th><th>Typical Range<\/th><\/tr><\/thead><tbody><tr><td>Individual IV infusion<\/td><td>$100 to $150<\/td><\/tr><tr><td>Initial workup (labs, consultation)<\/td><td>$200 to $500<\/td><\/tr><tr><td>20-infusion course<\/td><td>$2,000 to $3,000<\/td><\/tr><tr><td>40-infusion course (TACT protocol)<\/td><td>$4,000 to $6,000<\/td><\/tr><tr><td>Ongoing monitoring labs<\/td><td>$50 to $200 per draw<\/td><\/tr><tr><td>Monthly maintenance infusion<\/td><td>$100 to $150<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">Insurance rarely covers EDTA chelation for cardiovascular indications. It is typically covered for lead poisoning when ordered by a toxicologist. HSA and FSA accounts can generally be used for chelation therapy when prescribed by a licensed provider for a diagnosed medical condition.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Finding a Qualified Provider<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">If you are considering EDTA chelation, choosing the right provider is critical. Look for:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Training and certification:<\/strong> The American College for Advancement in Medicine (ACAM) offers training in chelation therapy. Board certification in integrative medicine, functional medicine, or toxicology provides relevant background.<\/li>\n<li><strong>Proper monitoring protocols:<\/strong> Any provider who skips baseline labs or does not monitor kidney function during treatment is cutting corners.<\/li>\n<li><strong>Evidence-based discussion:<\/strong> A good provider will discuss the TACT data honestly, including its limitations, and will not promise that chelation will cure heart disease.<\/li>\n<li><strong>Appropriate patient selection:<\/strong> Chelation is not for everyone. Patients with significant kidney impairment, severe heart failure, or certain blood disorders may not be appropriate candidates.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">The Bottom Line<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">EDTA chelation therapy sits at an interesting intersection of established science and evolving evidence. Its mechanism is well understood, its safety profile (when properly administered) is well documented, and the TACT trial provided the first rigorous evidence that it may have a legitimate role in cardiovascular medicine, particularly for diabetic patients with prior heart attacks.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">It is not a miracle cure for heart disease. It is not a substitute for proven cardiovascular therapies (statins, blood pressure medications, lifestyle modification). But for patients who have had a heart attack, especially those with diabetes, the TACT data suggests it may offer meaningful additional benefit. If TACT2 confirms these findings, the conversation will shift significantly.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">For a broader look at chelation therapy options and when they make sense, visit our <a href=\"\/blog\/chelation-therapy\/\">chelation therapy guide<\/a>. For more on potential side effects, see our article on <a href=\"\/blog\/chelation-therapy-side-effects\/\">chelation therapy side effects<\/a>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">References<\/h2>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Lamas GA, Goertz C, Boineau R, et al. Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial. <em>JAMA<\/em>. 2013;309(12):1241-1250. doi:10.1001\/jama.2013.2107<\/li>\n<li>Escolar E, Lamas GA, Mark DB, et al. The effect of an EDTA-based chelation regimen on patients with diabetes mellitus and prior myocardial infarction in the Trial to Assess Chelation Therapy (TACT). <em>Circ Cardiovasc Qual Outcomes<\/em>. 2014;7(1):15-24. doi:10.1161\/CIRCOUTCOMES.113.000663<\/li>\n<li>Lamas GA, Boineau R, Goertz C, et al. EDTA chelation therapy alone and in combination with oral high-dose multivitamins and minerals for coronary disease: the factorial group results of the Trial to Assess Chelation Therapy. <em>Am Heart J<\/em>. 2014;168(1):37-44.e5. doi:10.1016\/j.ahj.2014.02.012<\/li>\n<li>Lamas GA, Anstrom KJ, Aviles RJ, et al. The Trial to Assess Chelation Therapy 2 (TACT2): rationale and design. <em>Am Heart J<\/em>. 2022;252:1-11. doi:10.1016\/j.ahj.2022.05.013<\/li>\n<li>Flora SJ, Pachauri V. Chelation in metal intoxication. <em>Int J Environ Res Public Health<\/em>. 2010;7(7):2745-2788. doi:10.3390\/ijerph7072745<\/li>\n<li>Navas-Acien A, Guallar E, Silbergeld EK, Rothenberg SJ. Lead exposure and cardiovascular disease: a systematic review. <em>Environ Health Perspect<\/em>. 2007;115(3):472-482. doi:10.1289\/ehp.9785<\/li>\n<\/ol>\n\n\n\n<h2 class=\"wp-block-heading\">Related Reading<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"\/blog\/chelation-therapy\/\">Chelation Therapy: The Complete Guide<\/a><\/li>\n<li><a href=\"\/blog\/chelation-therapy-side-effects\/\">Chelation Therapy Side Effects: What to Know<\/a><\/li>\n<li><a href=\"\/blog\/heavy-metal-testing\/\">Heavy Metal Testing: Comparing Your Options<\/a><\/li>\n<li><a href=\"\/blog\/dmsa-chelation\/\">DMSA Chelation: How It Works and When It Is Used<\/a><\/li>\n<li><a href=\"\/blog\/regenerative-medicine-longevity\/\">Regenerative Medicine for Longevity<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>EDTA chelation therapy binds and removes heavy metals from the bloodstream. The NIH-funded TACT trial produced surprising results for cardiovascular disease. Here is what the evidence actually shows.<\/p>\n","protected":false},"author":1,"featured_media":6476,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_kad_post_transparent":"","_kad_post_title":"","_kad_post_layout":"","_kad_post_sidebar_id":"","_kad_post_content_style":"","_kad_post_vertical_padding":"","_kad_post_feature":"","_kad_post_feature_position":"","_kad_post_header":false,"_kad_post_footer":false,"_kad_post_classname":"","_regenerated_references":"","footnotes":""},"categories":[998,1011,992],"tags":[],"class_list":["post-5530","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-oxygen-energy-therapies","category-toxin-environmental-exposure","category-treatments"],"_links":{"self":[{"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/posts\/5530","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/comments?post=5530"}],"version-history":[{"count":1,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/posts\/5530\/revisions"}],"predecessor-version":[{"id":5845,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/posts\/5530\/revisions\/5845"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/media\/6476"}],"wp:attachment":[{"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/media?parent=5530"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/categories?post=5530"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regenerated.com\/blog\/wp-json\/wp\/v2\/tags?post=5530"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}